Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published April 2011
  • Article
  • Info & Metrics
  • PDF
Loading

SCH 900776 CHK1 Inhibitor

Guzi et al., Page 591

Targeted CHK1 inhibition is an attractive approach with the potential for rational combination with multiple chemotherapies. The critical issue is the therapeutic index in combination, necessitating careful selection of compounds for progression. Guzi and colleagues identified SCH 900776 using a pathway-oriented functional approach and targeted medicinal chemistry. Mechanism-based biomarkers were used to quantitatively assay checkpoint override phenotypes. This strategy exposed the risk of functional antagonism, highlighting a need for sufficient CHK1 selectivity. The biomarkers were translated to preclinical animal species, allowing in vivo assessment of SCH 900776 mechanism engagement and tolerability. In xenograft models, doses of SCH 900776 associated with robust biomarker activation, and improved tumor response was not associated with enhanced toxicity of gemcitabine on hematological parameters in BALB/c mice. Administration of SCH 900776 presents a clinical opportunity to selectively enhance cell death responses in tumor cell backgrounds.

Antibody–Human Endostatin Fusion Protein

Shin et al., Page 603

Since its discovery, endostatin, an important regulator of angiogenesis, has failed to have significant clinical impact. In this issue, Shin and colleagues enhance endostatin performance by tethering a mutant human endostatin to an anti-HER2 antibody. The antibody-endostatin fusion protein has a longer half life than endostatin, localizes to the tumor, and shows superior antiangiogenic efficacy in vitro and antitumor activity in vivo in tumor xenograft models. This promising approach points the way to more effective endostatin use in the clinic for breast cancer and other solid tumors and represents a new class of antiangiogenic agents.

mda-7 and IL-24 delE5 in Leukemia Differentiation

Yang et al., Page 615

Understanding mechanisms on leukemia differentiation may provide help for designing safe and specific differentiation therapy to treat leukemia. Yang and colleagues report that the induction of melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) and IL-24 delE5, a mda-7/IL-24 splice variant, contributes to 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced monocytic differentiation, and they also show the specific differentiation induction roles of mda-7/IL-24 and IL-24 delE5 in acute myeloid leukemia (AML) cells. These studies characterize mda-7/IL-24 and IL-24 delE5 as novel genes associated with leukemic cell differentiation and bring new insights into the regulation of AML cell differentiation.

CHK1 as a Therapeutic Target for BRCA2-Deficient Pancreatic Cancer

Hattori et al., Page 670

Genetic screens identifying molecules whose inactivation kills cancer cells carrying a specific genetic alteration (synthetic lethality) are widely used to select new therapeutic targets. Hattori and colleagues show an important limitation of synthetic lethal screens. They identify the checkpoint kinase CHK1 as a therapeutic target in cancers lacking the tumor suppressor BRCA2. However, CHK1 inhibition is rendered ineffective by additional mutations like activated KRAS or mutant TP53 typical of pancreatic cancers arising in BRCA2 mutation carriers. Gemcitabine overcomes this resistance. Synthetic lethal screens that fail to consider the full genetic context of specific malignancies may not identify valid therapeutic targets.

  • ©2011 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 10 (4)
April 2011
Volume 10, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther April 1 2011 (10) (4) 567;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther April 1 2011 (10) (4) 567;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • SCH 900776 CHK1 Inhibitor
    • Antibody–Human Endostatin Fusion Protein
    • mda-7 and IL-24 delE5 in Leukemia Differentiation
    • CHK1 as a Therapeutic Target for BRCA2-Deficient Pancreatic Cancer
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement